Navigation Links
Novexel Presents 16 Posters and one Slide Presentation at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Meeting in San Francisco
Date:9/11/2009

PARIS, September 11 /PRNewswire/ -- Novexel, a specialty pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces that its pipeline will be the subject of 16 posters and one slide presentation at the 49th annual meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The ICAAC meeting, which is taking place in San Francisco, California, September 12-15 2009, is the leading global conference on anti-microbial agents globally with over 10,000 participants.

    The posters presented at the conference cover:

    - NXL103, a novel oral streptogramin, which has completed a
      successful Phase II study in patients with community acquired pneumonia
      (CAP). It has been shown to be highly active against methicillin
      resistant Staphylococcus aureus (MRSA) and will soon start a Phase II
      trial in complicated Skin and Skin Surface infections (cSSSIs).

    - NXL104, Novexel's broad spectrum non-beta-lactam class A and
      C beta-lactamase inhibitor which, in combination with the cephalosporin
      antibiotic ceftazidime, is currently in two Phase II trials for
      complicated urinary tract infections (cUTIs) and complicated intra
      abdominal infections(cIAIs).

    NXL103
    NXL103 is the subject of 6 posters.

Poster L1-336 covers a Phase II trial which compared NXL103 with amoxicillin in the treatment of mild to moderate community acquired pneumonia (CAP) in adults. The trial showed that 500mg or 600mg of NXL103 twice a day was efficacious in the treatment of CAP and produced similar results to high dose amoxicillin. NXL103, which was generally well tolerated, may be an effective oral therapy for CAP and based on its spectrum, for complicated skin and skin structure infections (cSSSI).

Posters A1-1944, A1-1945 and A1-1946 c
'/>"/>

SOURCE Novexel
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Novexel Strengthens its Scientific Advisory Board With the Appointment of Dr. Karen Bush
2. Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009
3. PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
4. Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
5. iSEEK Enterprise Presents Collaboration with Penn Medicine at 2009 AMEE Conference
6. Viral Genetics Scientist Presents Potential New Treatment for Drug Resistant Brain Tumors at Aspen Symposium
7. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
8. Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association
9. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
10. Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress
11. Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... PROVO, Utah , July 10, 2014 ... genome annotation and interpretation, today announced an ... sequencing (NGS) analytics for Lineagen,s NextStep Dx ... evaluation of neurodevelopmental and neurological disorders, currently ... chromosomal microarray (CMA) testing service used by ...
(Date:7/10/2014)... --  Ceres, Inc . (Nasdaq: CERE ), ... results for the three months ended May 31, 2014 ... Ceres reported that the company and its customers have ... in Brazil, which concluded in June, despite dry and ... for part of the growing season. Yields of several ...
(Date:7/10/2014)... research may help in the fight against terrorism with ... quantities of explosives with the use of light and ... Sensors and Actuators B: Chemical , the researchers describe ... in concentrations as low as 6.3 ppm (parts per ... few minutes. , "Traditionally explosives detection has involved looking ...
(Date:7/10/2014)... journal PNAS (Proceedings of the National Academy of ... sleep deprivation have a significant effect on our metabolism. ... best time of day to test for diseases such ... effectively. , Researchers from the University of Surrey and ... between sleep deprivation, body clock disruption and metabolism, and ...
Breaking Biology Technology:Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Detecting trace amounts of explosives with light 2Time of day crucial to accurately test for diseases, new research finds 2
... , SEATTLE, Sept. 10 Cell Therapeutics, Inc. ... the Biotech Industry conference on Wednesday, September 16, 2009, at 10:30 AM ... 16, 2009, at the Millennium Broadway Hotel in New York. The ... the presentation. The webcast can be accessed at www.celltherapeutics.com ...
... , CARLISLE, Pa., Sept. 9 Hanson ... pathogen screening, today announced the issuance of a U.S. Patent ... Microorganisms. The U.S. patent describes the Company,s method for screening ... and other plant material intended for human and animal consumption. ...
... , CAMBRIDGE, Mass., Sept. 9 ... development of next-generation cellulosic ethanol and high-performance specialty enzymes, announced that ... at 5:00 p.m. today. Verenium,s shares will continue to trade ... letter "D" added to the end of the trading symbol for ...
Cached Biology Technology:Hanson Technologies, Inc. Awarded Patent for its Advanced Food Pathogen Detection System 2Verenium 1:12 Reverse Stock Split Takes Effect 2Verenium 1:12 Reverse Stock Split Takes Effect 3Verenium 1:12 Reverse Stock Split Takes Effect 4
(Date:7/11/2014)... University of Chicago is creating a new professorship ... the University,s Institute for Molecular Engineering and the ... donation from the Millicent and Eugene Bell Foundation., ... reside within the Institute for Molecular Engineering. That ... project at the MBL,s Eugene Bell Center for ...
(Date:7/11/2014)... 3, 2014, Shenzhen, China Researchers from Salk Institute ... the first time evaluated the safety and reliability ... successfully developed a new method, TALEN-HDAdV, which could ... stem cell (hiPSC). This study published online in ... theoretical foundation for stem cell-based gene therapy. , ...
(Date:7/11/2014)... 11, 2014 The increased risk of kidney injury ... resuscitation fluids reflects the mass of HES molecules, according ... official journal of the International Anesthesia Research Society (IARS). ... harmful effect of HES on cultured human renal proximal ... Christian Wunder and colleagues of University Hospital Wrzburg, Austria. ...
Breaking Biology News(10 mins):New professorship in tissue engineering links molecular engineering, marine biology 2A new genome editing method brings the possibility of gene therapies closer to reality 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... from blood poisoning? To answer this question, the doctor draws ... for testing. This takes up valuable time, which could cost ... to analyze blood there and then and have the results ... developed by scientists at the Fraunhofer Institute for Physical Measurement ...
... considering scores of applications to develop utility-scale solar power ... but too little is known to judge their likely ... the December 2011 issue of BioScience . Although ... technology, available information suggests a worrisome range of possible ...
... ARLINGTON, Va.Underscoring the importance of alternative energy for the ... Corps Base Hawaii Dec. 7 to learn about possible ... Research (ONR)-funded fuel cell vehicles (FCV) and high-efficiency trash ... the 70th anniversary of the Pearl Harbor attack, was ...
Cached Biology News:Recognizing blood poisoning quickly 2Solar power development in US Southwest could threaten wildlife 2New energy sources fuel interest from Secretary of the Navy 2
... Jouan MSC series of Class II ... conditions and certification to the world's ... ensures that the cabinets cannot be ... Natural lighting, low noise and arm ...
... to create the ideal environment for nucleic acid ... , Variable speed control (10 to 15 ... be for washing or hybridizing , A ... the chamber, ,is situated above a touch sensitive ...
... engineered for efficient drying down of synthetic ... cover and a post-trap with ammonia neutralizing ... of samples in ammonium hydroxide., , ... , Comes standard with ...
... MB (for aqueous, other low volatility and ... respond to specific applications of molecular biology ... of heat-labile samples. The RC systems can ... traps and a wide selection of rotors ...
Biology Products: